Latest news with #LarryMiller
Yahoo
24-05-2025
- Business
- Yahoo
Jordan Brand's Larry Miller Redefines Second Chances For Formerly Incarcerated Through A Workforce And Education Initiative
Chairman of the Jordan brand Larry Miller announced a new initiative that gives second chances to formerly incarcerated persons with criminal pasts–just like him. With the help of his daughter, Laila Lacy, Miller launched the Justice and Upward Mobility Project also known as JUMP to push the formerly incarcerated to the top of hiring managers and chief human resources officers' pool of resumes. Known as a highly ignored demographic, Miller is using his own story of being rejected by then-Big Eight public accounting firm Arthur Andersen when he told the hiring manager the truth about his past. Years prior, Miller had spent time in a juvenile correction center for his role in the death of another teenager that he mistakenly thought was from a rival gang. After fighting for years to turn his life around, Miller was concerned his secret would get out. 'Every day I'm worried that somehow the story is going to get out and it's going to destroy everything that I had built up to that point,' he remembered while speaking at Fortune's Workplace Innovation Summit. The work of JUMP is targeted at correcting this wrong while living in digital days, making it harder for the past to be hidden. Supported by corporate partners like NBCUniversal, Cisco, Jobs for the Future, and the Corporate Coalition of Chicago, according to Forbes, the initiative focuses on four pillars of education and employment, advocacy and policy, media and narrative, and coalition building. The first pillar of education and employment focuses on creating workforce development programs that showcase opportunities to youths and adults still tied up in the justice system. Data from the Harvard Business Review showed persons that once spent time behind bars have a 77% of returning between two and three years — but not without a trade. The number drops to 30% if that formerly incarcerated person learns a skill and decreases more to six percent if they obtain a bachelor's degree. While encouraging participants to foster relationships with employers in the sports, entertainment, and business fields, Miller's JUMP is committed to working with policymakers at the local, state, and federal level in effort to curate supportive legislation geared toward education and workforce development. It will also help limit barriers for people with arrest records to gain employment, hence giving second chances to those labeled with a negative perception. To the former Portland Trailblazer president, the data proves that there is a space for the formerly imprisoned to thrive. 'To me, that's a clear indication that if people are able to learn a trade, get an education—do something that allows them to rebuild their life, take care of their families, and get back to their communities, people don't go back to jail,' he said. 'That should be the goal.' RELATED CONTENT: Jordan Brand Unveils Jordan Melo 10
Business Wire
22-05-2025
- Business
- Business Wire
Phibro Animal Health Corporation to Participate at Stifel Jaws & Paws Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Stifel Jaws & Paws Conference. Chief Operating Officer, Larry Miller along with Director and Executive Vice President, Corporate Strategy, Daniel Bendheim will address financial analysts and investors on Thursday, May 29, 2025, at 8:35 AM ET at the Lotte New York Hotel in New York. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit Our filings with the Securities and Exchange Commission are available online at or on request from the company.
Yahoo
19-05-2025
- Health
- Yahoo
Apnimed Announces Positive Topline Results in the First Landmark Phase 3 Clinical Trial of AD109, an Investigational Once-daily Oral Pill for Obstructive Sleep Apnea
AD109 met the primary endpoint, mean change in apnea-hypopnea index (AHI, p=0.001) at 26 weeks, across a broad range of people with mild, moderate and severe obstructive sleep apnea Study participants treated with AD109 achieved a mean reduction in AHI of 55.6% from baseline and achieved significantly improved oxygenation and reduced disease severity AD109 is a first-in-class, anti-apneic neuromuscular modulator which targets the root cause of OSA by increasing upper airway muscle tone during sleep Apnimed expects topline results in Q3'25 from its second Phase 3 clinical trial, LunAIRo, and plans to submit an NDA to the U.S. FDA for AD109 by early 2026 CAMBRIDGE, Mass., May 19, 2025 /PRNewswire/ -- Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of Apnimed's lead candidate AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in adults living with mild, moderate and severe OSA, and across all weight classes. The SynAIRgy trial met its primary endpoint: mean change from baseline in the apnea-hypopnea index (AHI) at 26 weeks compared to placebo (p=0.001). The topline results for the primary and multiple secondary endpoints were similar to the results observed in the previous 4-week MARIPOSA Phase 2b clinical trial. AD109 was generally well-tolerated, and the most common adverse events were consistent with earlier AD109 clinical trials. No serious adverse events related to AD109 were reported in the SynAIRgy trial. An estimated 80 million people in the United States and one billion people worldwide are living with OSA. OSA is caused by two overlapping mechanisms: neuromuscular dysfunction during sleep and predisposing anatomic abnormalities. AD109 is designed to target the neurobiology of the hypoglossal motor nucleus by increasing signals to the upper airway muscles during sleep, leading to the reduction or prevention of upper airway collapse. "Today is a landmark moment for Apnimed and for millions living with OSA who have long struggled with limited treatment options," said Larry Miller, MD, Chief Executive Officer of Apnimed. "The positive results from our Phase 3 SynAIRgy trial bring us closer to realizing our vision of offering a simple, safe, and effective oral drug — one that is grounded in science, driven by unmet need, and centered on people with OSA. We believe these results represent the dawn of a new era in the OSA treatment paradigm. We are deeply grateful to the patients, investigators, and clinical teams whose partnership and commitment made this achievement possible. Importantly, these results increase our confidence in the expected outcome of the second Phase 3 clinical trial, LunAIRo, with topline results expected in Q3'25." Additional Efficacy ResultsIn addition to meeting the primary endpoint, AD109 also demonstrated improvements in other secondary and exploratory endpoints, including: Meaningful improvements in oxygenation as assessed by hypoxic burden (p<0.0001) and oxygen desaturation index (p=0.001) 51.2% of participants treated with AD109 showed a reduction in OSA disease severity category 22.3% of participants treated with AD109 achieved complete OSA disease control (defined as AHI <5 events/hour) "These Phase 3 topline results are highly encouraging and represent the potential for a much-needed innovation in the treatment of OSA," said Patrick Strollo, Jr., MD, study chair of the SynAIRgy clinical trial and Vice Chair of Medicine for Veteran's Affairs at the University of Pittsburgh School of Medicine. "For too long, progress in OSA has been limited, leaving many people with OSA without sustainable treatment options. The results from SynAIRgy suggest that if approved, AD109 could offer a compelling new treatment option — a novel oral drug that targets the neuromuscular root cause of airway obstruction in sleep apnea and holds promise for transforming care for a broad range of patients." "OSA should be considered a top public health priority: it is a serious, common, chronic disease that affects a wide range of people, impacting both males and females of all age groups, ethnicities, and weight classes, including those with or without obesity," said Monica Mallampalli, PhD, President and CEO of the Alliance of Sleep Apnea Partners. "There is a vast need for new treatment options. We welcome innovations like this, which are long overdue for our patient community. The SynAIRgy results offer people hope that an oral therapy is on the horizon that could make it easier for them to manage their OSA and reclaim their lives." Advancing AD109Apnimed plans to submit a New Drug Application (NDA) for AD109 to the U.S. Food and Drug Administration (FDA) by early 2026 for regulatory review. The full data for SynAIRgy will be presented at a medical congress later this year and published in a peer-reviewed scientific journal. Apnimed also anticipates the availability of topline data in Q3 2025 from the second Phase 3 LunAIRo trial, a one-year study of AD109 in adults with OSA. About the SynAIRgy StudyThe SynAIRgy study (NCT05813275) was a randomized, double blind, placebo-controlled, parallel-arm six-month clinical trial of AD109, a fixed dose combination of aroxybutynin 2.5mg/atomoxetine 75mg, in participants with OSA who are intolerant of or currently refuse continuous positive airway pressure (CPAP) therapy. The trial enrolled 646 adult participants from 73 centers in the US and Canada. Participants were randomized 1:1 to either AD109 or placebo and instructed to take their assigned treatment once-daily before bedtime. SynAIRgy is the largest Phase 3 clinical trial of a medication to treat OSA. Enrolled participants in SynAIRgy were representative of the real-world patient population, including the diverse demographic composition of the United States and the typical profiles seen in a sleep clinic population. Participants included 49.1% females, multiple racial groups, and varied weight classes spanning healthy weight, overweight, and with obesity. Participants were distributed across OSA severity levels, including mild (34.4%), moderate (42.4%), and severe (23.2%). Participants had symptoms reflective of the OSA patient experience. About AD109AD109 is designed to be the first pharmacological treatment to improve oxygenation during sleep by directly addressing the neuromuscular root cause of upper airway collapse in people with obstructive sleep apnea. It is a first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor (NRI). Their combined pharmacological synergy targets the underlying neuromuscular cause of OSA. AD109 is a once-daily pill taken at bedtime that is designed to lower the complexity of intervention and may help more people benefit from effective, restorative sleep. In a disease characterized by complex and invasive treatment options, AD109 may be a simple solution to help improve oxygenation and health wellbeing for people living with OSA. About Obstructive Sleep ApneaObstructive sleep apnea (OSA) is a serious, chronic sleep-related breathing disease in which the upper airway repeatedly collapses during sleep, leading to intermittent oxygen deprivation. It is caused by two overlapping mechanisms: neuromuscular dysfunction during sleep and predisposing anatomic abnormalities. OSA affects individuals across all walks of life, impacting both males and females of all age groups, ethnicities, and weight classes, including those with or without obesity. An estimated 80 million people in the United States and one billion people worldwide suffer from OSA. Up to 80% of people living with OSA are undiagnosed and therefore untreated. An individual with OSA can experience hundreds of sleep apnea events in a single night, each one reducing the blood oxygen levels and negatively impacting cellular functions vital to normal health and function. Failure to effectively treat OSA increases the risk of serious long-term health consequences, including cardiovascular disease, neurocognitive impairment, metabolic dysfunction, and early mortality. Yet, the majority of those diagnosed with OSA refuse, abandon, or underutilize treatment. Currently, no available pharmacological treatments directly address the underlying neuromuscular dysfunction that is present in OSA. About ApnimedApnimed is a privately held clinical-stage pharmaceutical company dedicated to transforming the treatment landscape for sleep-related breathing diseases. We believe the introduction of simple, once-nightly oral drugs has the potential to dramatically expand diagnosis and the reach of treatment for people with OSA. OSA, like other common chronic diseases such as diabetes or hypertension, would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people get the oxygen and restorative sleep needed to thrive. Based in Cambridge, Mass., Apnimed is advancing a robust pipeline of oral pharmaceutical product candidates designed to improve oxygenation in individuals living with OSA and other sleep-related breathing disorders. Our lead candidate, AD109, could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 is currently in Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Apnimed is also developing several therapies as part of its joint venture with Shionogi & Co., Ltd., Shionogi-Apnimed Sleep Science. Learn more at or follow us on X and LinkedIn. Media Contact: media@ Investor Contact:ir@ View original content to download multimedia: SOURCE Apnimed, Inc. Sign in to access your portfolio
Reuters
14-05-2025
- Sport
- Reuters
Former North Carolina star, ABA standout Larry Miller dies at 79
May 14 - Former North Carolina and ABA great Larry Miller, a 2022 College Basketball Hall of Fame inductee, died on Sunday. He was 79. North Carolina said Miller died in Bethlehem, Pa. He reportedly had been battling medical issues. Miller was a two-time Atlantic Coast Conference Player of the Year during his three seasons (1965-68) with the Tar Heels. He still ranks ninth in school history with 1,982 career points in 91 games and had career averages of 21.8 points and 9.2 rebounds. Miller averaged over 20 points in all three of his seasons and scored in double figures in 64 straight games, a still-standing school mark. As a senior, Miller averaged 22.4 points and 8.1 rebounds while being a consensus first-team All-American on an epic squad that included UCLA's Lew Alcindor (later Kareem Abdul-Jabbar), Houston's Elvin Hayes, LSU's Pete Maravich and Louisville's Wes Unseld. Miller was a fifth-round pick in the 1968 NBA draft but instead opted to play in the upstart ABA and had a seven-year pro career. His biggest moment came when he was a member of the Carolina Cougars and set the ABA single-game scoring record of 67 points in a 139-125 victory over the Memphis Pros on March 18, 1972 at Greensboro, N.C. Miller made 25 of 40 field-goal attempts and 17 of 23 from the free-throw line. He missed his lone 3-point shot. Miller averaged 13.6 points and 5.0 rebounds in 486 career ABA games. --Field Level Media
NBC Sports
13-05-2025
- Sport
- NBC Sports
Larry Miller, star on North Carolina's ACC championship teams in 1967-68, dies at age 79
CHAPEL HILL, N.C. — Larry Miller, a two-time ACC player of the year for North Carolina and 2022 inductee in the College Basketball Hall of Fame, has died. He was 79. The UNC athletic department said Miller died Sunday in Bethlehem, Pennsylvania. No cause of death was given. An athletic department spokesman said Miller was in hospice care and dealing with medical issues for some time. Miller, a native of Catasauqua, Pennsylvania, was a star forward on coach Dean Smith's first two Atlantic Coast Conference championship and Final Four teams in 1967 and 1968. He earned first-team All-America honors both seasons and was a consensus pick in 1968 along with UCLA's Lew Alcindor, Houston's Elvin Hayes, LSU's Pete Maravich and Louisville's Wes Unseld. Miller scored in double figures in 64 consecutive games, still a UNC record. Miller scored 1,982 points in three seasons and averaged 21.8 points, the fifth-highest by a Tar Heel. In one of his most memorable performances, he scored 32 points on 13-of-14 shooting from the field in an 82-73 victory over Duke in the 1967 ACC championship game. Led by Miller, Carolina went 70-21, including 32-10 in ACC regular-season play, from 1965-68. The Tar Heels were No. 4 in the final Associated Press polls his last two seasons, the first time Carolina was ranked in the top 10 in the final poll in consecutive seasons. Miller played seven years in the ABA and set the league's all-time single-game record with 67 points.
